Roche: We’ve Abandoned Budgets And It’s Liberated Employees
Bill Anderson says Roche has scrapped budgets and improved productivity and re-energised teams. But is it too good to be true?
You may also be interested in...
Bill Anderson is leaving Roche after leading its pharma division through the loss of three oncology blockbusters and the launch of a new generation of blood cancer therapies.
Many new and pipeline products were highlighted at London meeting – but no word on Spark Therapeutics deal. New products will have high profit margins.
Seven years after a major shift in how the company compensated its sales force, the UK major has done a U-turn and is adapting pay packages for some specialty care reps.